Greenyn Biotechnology Co Ltd

Greenyn Biotechnology maintains a debt-to-equity ratio of 0.94, indicating a moderate reliance on debt financing, while its current ratio of 6.84 suggests strong short-term liquidity. However, the company's free cash flow is negative at -311.26 million TWD, and capital expenditures are -395.08 million TWD, signaling significant reinvestment in operations. The company's return on equity of 14.87% and return on assets of 6.9% outperform the median for the Pharmaceuticals industry, suggesting efficient use of equity and assets. The company's profitability is supported by a gross margin of 48.07% (440.04 million TWD gross profit on 915.32 million TWD revenue) and an operating margin of 20.61% (188.64 million TWD operating income). These metrics align with the industry's preferred profitability indicators, which emphasize gross and operating margins as key performance indicators. However, the company's net income of 145.52 million TWD represents a net margin of 15.89%, which is slightly below the cohort median for its industry. Greenyn's revenue is concentrated in three business segments: health ingredients, health formulations, and other products. The company's geographic exposure is primarily in Taiwan and other Asian regions, with no disclosed revenue breakdown by region. This concentration may expose the company to regional economic or regulatory risks, particularly in the health food and pharmaceutical sectors. The company's growth trajectory is mixed. While its current fiscal year (FY) revenue is 915.32 million TWD, the outlook for the next FY is uncertain due to the absence of disclosed revenue growth projections. The company's capital expenditures and negative free cash flow suggest a focus on expansion and operational reinvestment, which could support long-term growth but may pressure short-term liquidity. Greenyn faces a medium liquidity risk due to its negative net cash position after subtracting total debt, and a low dilution risk based on its current share structure. The company has not disclosed any recent share issuance or dilution events, and its diluted and basic shares outstanding are equal at 27.03 million. No adjustments have been applied to its valuation metrics, indicating that the company's financials are presented without material non-GAAP adjustments. Recent filings and transcripts do not disclose any material events or strategic shifts for Greenyn Biotechnology. The company's operations remain focused on health food raw materials and formulations, with no indication of diversification or new product lines in the latest available data.